Certara (NASDAQ:CERT) Hits New 52-Week Low – Here’s What Happened

Certara, Inc. (NASDAQ:CERT)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $7.90 and last traded at $7.8450, with a volume of 1090826 shares trading hands. The stock had previously closed at $8.30.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wall Street Zen lowered Certara from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. Redburn Partners set a $10.00 price target on Certara in a research note on Friday, November 21st. Morgan Stanley cut their price objective on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. KeyCorp lowered their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.58.

Certara Trading Down 3.0%

The company’s 50 day moving average price is $9.10 and its 200 day moving average price is $10.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm has a market cap of $1.18 billion, a PE ratio of 105.43 and a beta of 1.47.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The firm had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same period in the prior year, the firm earned $0.13 EPS. As a group, analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CERT. AQR Capital Management LLC purchased a new position in shares of Certara in the 1st quarter valued at about $259,000. Goldman Sachs Group Inc. lifted its stake in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after acquiring an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after acquiring an additional 35,954 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Certara by 17.1% in the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in shares of Certara by 25.3% during the 2nd quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock worth $66,391,000 after purchasing an additional 1,145,554 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.